Collective Synthesis and Biological Evaluation of Tryptophan‐Based Dimeric Diketopiperazine Alkaloids
S Tadano, Y Sugimachi, M Sumimoto… - … A European Journal, 2016 - Wiley Online Library
A concise two one‐pot synthesis of WIN 64821, eurocristatine, 15, 15′‐bis‐epi‐
eurocristatine, ditryptophenaline, ditryptoleucine A, WIN 64745, cristatumin C, asperdimin …
eurocristatine, ditryptophenaline, ditryptoleucine A, WIN 64745, cristatumin C, asperdimin …
Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR
J Yan, Y Xu, X Jin, Q Zhang, F Ouyang, L Han… - European Journal of …, 2022 - Elsevier
Microtubule target agents (MTAs) are widely-used clinical anti-cancer drugs for decades, but
the acquired drug resistance severely restricted their application. Thioredoxin reductases …
the acquired drug resistance severely restricted their application. Thioredoxin reductases …
[HTML][HTML] Pharmacological actions of multi-target-directed evodiamine
H Yu, H Jin, W Gong, Z Wang, H Liang - Molecules, 2013 - mdpi.com
Evodiamine, a naturally occurring indole alkaloid, is one of the main bioactive ingredients of
Evodiae fructus. With respect to the pharmacological actions of evodiamine, more attention …
Evodiae fructus. With respect to the pharmacological actions of evodiamine, more attention …
Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers
Evodiamine is a major alkaloid component found in the fruit of Evodia rutaecarpa. It shows
the anti-proliferative potential against a wide range of cancers by suppressing cell growth …
the anti-proliferative potential against a wide range of cancers by suppressing cell growth …
Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis
ER Welin, A Ngamnithiporn, M Klatte, G Lapointe… - Science, 2019 - science.org
The bis-tetrahydroisoquinoline (bis-THIQ) natural products have been studied intensively
over the past four decades for their exceptionally potent anticancer activity, in addition to …
over the past four decades for their exceptionally potent anticancer activity, in addition to …
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
R Fu, Y Sun, W Sheng, D Liao - European journal of medicinal chemistry, 2017 - Elsevier
The dominant paradigm in drug discovery is to design ligands with maximum selectivity to
act on individual drug targets. With the target-based approach, many new chemical entities …
act on individual drug targets. With the target-based approach, many new chemical entities …
Escherichia coli Allows Efficient Modular Incorporation of Newly Isolated Quinomycin Biosynthetic Enzyme into Echinomycin Biosynthetic Pathway for Rational …
K Watanabe, K Hotta, M Nakaya… - Journal of the …, 2009 - ACS Publications
Natural products display impressive activities against a wide range of targets, including
viruses, microbes, and tumors. However, their clinical use is hampered frequently by their …
viruses, microbes, and tumors. However, their clinical use is hampered frequently by their …
[HTML][HTML] Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa
J Jiang, C Hu - Molecules, 2009 - mdpi.com
Traditional Chinese herbs are regarded as a new and promising source of potential anti-
cancer remedies and new chemotherapy adjuvants to enhance the efficacy of chemotherapy …
cancer remedies and new chemotherapy adjuvants to enhance the efficacy of chemotherapy …
Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation
VEGF/VEGFR2 pathway is the crucial therapeutic target in the treatment of cancer. So that, a
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …
new series of quinoxaline-2 (1H)-one derivatives were designed and synthesized. The …
Discovery of novel multiacting topoisomerase I/II and histone deacetylase inhibitors
S He, G Dong, Z Wang, W Chen, Y Huang… - ACS Medicinal …, 2015 - ACS Publications
Designing multitarget drugs remains a significant challenge in current antitumor drug
discovery. Because of the synergistic effect between topoisomerase and HDAC inhibitors …
discovery. Because of the synergistic effect between topoisomerase and HDAC inhibitors …